# A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

> **NCT00503477** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** AZD2171

## Key facts

- **NCT ID:** NCT00503477
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-07
- **Final completion:** 2009-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503477, "A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00503477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*